Tesaro’s ovarian cancer drug shows benefit in late-stage trial

By: | Published: June 29, 2016 5:21 PM

The cancer drug, niraparib, improved progression-free survival in certain ovarian cancer patients.

(Reuters)The ovarian cancer drug by Tesaro is meeting the main goal of prolonging survival in patients. (Reuters)

Tesaro Inc said its ovarian cancer drug met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares up 69 percent in premarket trading.

The drug, niraparib, improved progression-free survival in certain ovarian cancer patients. The study enrolled more than 500 subjects.

The median progression-free survival for patients treated with niraparib was 21 months, compared to 5.5 months for those on a placebo.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition